Loading...

Home
ETF
TCRT

TCRT

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

TCRT News

Alaunos Therapeutics Reveals Promising ALN1003 Preclinical Data

Mar 02 2026Benzinga

Alaunos' ALN1003 Drug Candidate Shows Weight Loss Potential

Mar 02 2026Newsfilter

4 Biotech Stocks Experiencing Decline: Momentum Scores Diminishing in the Last Week

Sep 03 2025Benzinga

PMGC Capital LLC Urges Alaunos Therapeutics (NASDAQ: TCRT) to Accept Term Sheet from Leading Wall Street Bank Behind Many Leading Crypto Strategies

Jun 18 2025Globenewswire

PMGC Capital LLC, a Subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), To File Schedule 13D Reporting 5.09% Stake in Alaunos Therapeutics, Inc. (Nasdaq: TCRT)

May 14 2025Newsfilter

TCRT Stock Earnings: Alaunos Therapeutics Reported Results for Q2 2024

Aug 16 2024Business Insider

Why Domino's Pizza Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Jul 18 2024Benzinga

TCRT Stock Earnings: Alaunos Therapeutics Reported Results for Q1 2024

May 16 2024Business Insider

Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives

Nov 13 2023businesswire

Alaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim Clinical Data and Exploration of Strategic Alternatives

Aug 14 2023globenewswire

Alaunos Therapeutics Announces Presentation at the 2nd Hawaii Global Summit on Thoracic Malignancies

Jun 28 2023globenewswire

Alaunos Therapeutics to Present Early Data from TCR-T Library Phase 1/2 Trial at 2023 American Society of Clinical Oncology Annual Meeting

May 25 2023globenewswire

Alaunos Therapeutics Reports First Quarter 2023 Financial Results

May 09 2023globenewswire

Alaunos Therapeutics to Report First Quarter 2023 Financial Results on May 10, 2023

May 03 2023globenewswire

Alaunos Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

Apr 26 2023globenewswire

Alaunos Therapeutics Appoints Dr. Robert J. Hofmeister to Board of Directors

Mar 29 2023globenewswire